Matthew L. Trerotola Sells 6,743 Shares of Enovis Co. (NYSE:ENOV) Stock

Enovis Co. (NYSE:ENOVGet Rating) CEO Matthew L. Trerotola sold 6,743 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $57.69, for a total transaction of $389,003.67. Following the sale, the chief executive officer now owns 197,388 shares in the company, valued at approximately $11,387,313.72. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Enovis Price Performance

ENOV opened at $55.32 on Friday. The stock has a 50-day moving average price of $59.82 and a 200-day moving average price of $54.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.41 and a quick ratio of 0.65. The firm has a market cap of $3.01 billion, a PE ratio of -276.59 and a beta of 2.01. Enovis Co. has a 1 year low of $43.88 and a 1 year high of $123.32.

Enovis (NYSE:ENOVGet Rating) last announced its quarterly earnings results on Thursday, February 23rd. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. Enovis had a negative net margin of 0.46% and a positive return on equity of 3.30%. The firm had revenue of $409.00 million for the quarter, compared to the consensus estimate of $415.79 million. During the same quarter last year, the firm posted $1.77 EPS. The business’s quarterly revenue was down 60.0% compared to the same quarter last year. Sell-side analysts predict that Enovis Co. will post 2.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enovis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD bought a new position in shares of Enovis during the 2nd quarter valued at $333,199,000. T. Rowe Price Investment Management Inc. lifted its holdings in Enovis by 0.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,040,170 shares of the company’s stock valued at $323,270,000 after acquiring an additional 30,198 shares during the period. Vanguard Group Inc. boosted its position in Enovis by 1.0% in the third quarter. Vanguard Group Inc. now owns 4,482,428 shares of the company’s stock worth $206,505,000 after purchasing an additional 43,799 shares during the last quarter. BlackRock Inc. grew its stake in shares of Enovis by 0.4% during the 3rd quarter. BlackRock Inc. now owns 4,279,254 shares of the company’s stock valued at $197,144,000 after purchasing an additional 15,108 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Enovis by 19.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,762,799 shares of the company’s stock valued at $147,867,000 after purchasing an additional 450,715 shares during the last quarter. Hedge funds and other institutional investors own 96.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ENOV shares. Robert W. Baird dropped their target price on shares of Enovis from $68.00 to $64.00 and set an “outperform” rating on the stock in a report on Friday, February 24th. Evercore ISI lifted their price target on Enovis to $68.00 in a research report on Tuesday, January 3rd. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from, the company presently has an average rating of “Moderate Buy” and a consensus price target of $63.00.

About Enovis

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Read More

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with's FREE daily email newsletter.